Brunkan, 2004 - Google Patents
Characterization of domains important for stabilization and maturation of the Alzheimer's disease protein presenilin-1, and their impact on presenilinase and gamma …Brunkan, 2004
- Document ID
- 17777026683700544338
- Author
- Brunkan A
- Publication year
External Links
Snippet
Alzheimer's disease (AD) is the most common form of progressive dementia and the fourth leading cause of death in the United States. Mutations in the genes encoding β-amyloid precursor protein (APP) and the presenilins (PS1, PS2) account for the majority of familial …
- 230000000694 effects 0 title abstract description 248
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smit et al. | Reactive astrocytes as treatment targets in Alzheimer's disease—systematic review of studies using the APPswePS1dE9 mouse model | |
| Brunkan et al. | Presenilin function and γ‐secretase activity | |
| Crowther et al. | Intraneuronal Aβ, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer’s disease | |
| Zheng et al. | Biology and pathophysiology of the amyloid precursor protein | |
| Zhang et al. | Proteolytic processing of Alzheimer’s β‐amyloid precursor protein | |
| Sisodia et al. | Role of the β‐amyloid protein in Alzheimer's disease | |
| Müller et al. | Physiological functions of APP family proteins | |
| Roberts et al. | α-Synuclein increases β-amyloid secretion by promoting β-/γ-secretase processing of APP | |
| Konietzko | AICD nuclear signaling and its possible contribution to Alzheimer's disease | |
| Greenfield et al. | Cellular and molecular basis of beta-amyloid precursor protein metabolism | |
| Brunkan | Characterization of domains important for stabilization and maturation of the Alzheimer's disease protein presenilin-1, and their impact on presenilinase and gamma-secretase activity | |
| US20040038338A1 (en) | Influence of LRP cytoplasmic domain on Abeta production | |
| Wahrte et al. | Apolipoprotein E, amyloid b peptide, and Alzheimer’s disease | |
| Dolfe | BRICHOS interactions with amyloid proteins and implications for Alzheimer disease | |
| Alexander | Elucidating the Role of APL-1, the C. Elegans Ortholog of the Human Amyloid Precursor Protein | |
| Savaglio | Confirmation and Characterization of a Functional APP/GAP-43 Protein Interaction | |
| MacKinnon | Investigating glial roles of Alzheimer’s disease risk genes, using drosophila models | |
| Hedskog | Mitochondria in Alzheimer disease: regulatory mechanisms and cell death | |
| Sivananthan | The inheritance of loss: Caspase-6 activity and effect in human neurons caused by familial Alzheimer's Disease associated mutants | |
| Huynh | The Role of Apolipoprotein E in Alzheimer Disease: From Therapy to Mechanism | |
| WO2023143610A2 (en) | C-TERMINAL FRAGMENT OF APOLIPOPROTEIN E AND APPLICATION THEREOF IN INHIBITING γ-SECRETASE ACTIVITY | |
| Glenner et al. | The Potamkin prize for research in Pick’s, Alzheimer’s and related diseases | |
| Wanngren | Molecular studies of the γ-secretase complex: focus on genetic and pharmacological modulation | |
| Midthune | The role of amyloid precursor protein in amyloid-beta-mediated synaptic dysfunction | |
| Rudan Njavro | Function and substrates of the Alzheimer´ s disease protease BACE1 |